Treatment

LIVTENCITY 200 mg film-coated tablets. clinical trials

1 indexed studies · 0 currently recruiting

AuthorisedTherapeutic use (Phase IV)
A phase IV proof-of-concept study to assess the safety and efficacy of Maribavir to inhibit high Virus Epstein-Barr (VEB) replication among young adult kidney transplant recipie
This study looks at a medicine called Maribavir (LIVTENCITY) for young adults who have had a kidney transplant and are dealing with a common viral infection caused by the Epstein-Barr virus (EBV). Doctors want to see how well it clears the virus and if it's safe.
For: Transplant patients with high recurrent Epstein-Barr infection
Spain